Compounds > lactic acid

lactic acid and ribavirin

lactic acid has been researched along with ribavirin in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Breitenecker, F; Gangl, A; Kosi, L; Maresch, J; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Wrba, F	1
Ishihara, T; Kaneko, K; Mizushima, T	1

Other Studies

4 other study(ies) available for lactic acid and ribavirin

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. The Journal of infectious diseases, 2010, Jul-01, Volume: 202, Issue:1 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Gene Expression Regulation; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; L-Lactate Dehydrogenase; Lactic Acid; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2010
Development of biodegradable nanoparticles for liver-specific ribavirin delivery. Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:12 Topics: Animals; Antiviral Agents; Biocompatible Materials; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Excipients; Female; Galactans; Hep G2 Cells; Hepatitis C, Chronic; Humans; Lactic Acid; Liver; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polylysine; Polymers; Ribavirin	2014